Table 6. Agreement rate, underestimate and overestimate rates for the different primary diagnostic procedures.
| Surgical biopsy | FNA US-guided | LCNB US-guided | LCNB stereotactic | COBRA study | |
|---|---|---|---|---|---|
| Needle (gauge) | 22G | 18G+14G | 14G | 14G | |
| n= | 316 | 148 | 89 | 54 | 858 |
| Nonconclusive (%) | 1.2 | 29 | 4 | 3 | 1.5 |
| Agreement rate (%) | Not applicable | 87 | 86 | 85 | 93 |
| Miss rate (%) | 2 | 5 | 12 | 8 | 3 |
| Sensitivity (%) | 98 | 95 | 88 | 92 | 97 |
| High risk underestimate rate (%)a | 9 | Not applicable | 33 | 40 | 23 |
| DCIS underestimate rate (%)b | 8 | Not applicable | 37 | 27 | 17 |
| DCIS overestimate rate (%)c | Not applicable | 9 | Not applicable | Not applicable | Not applicable |
a
High-risk underestimate is defined as the finding of ADH, lobular carcinoma in situ without malignancy in the diagnostic material, but with carcinoma (in situ or invasive), in the surgical specimen
b
DCIS underestimate is defined as the finding of DCIS without invasive carcinoma in the diagnostic material, but with invasive carcinoma in the therapeutical specimen
c
DCIS overestimate is defined as the finding of malignant cells on cytology and DCIS without invasive carcinoma in the surgical specimen. US-guided=ultrasound guided.